These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26854807)

  • 1. Rate and predictors of progression in elite and viremic HIV-1 controllers.
    Leon A; Perez I; Ruiz-Mateos E; Benito JM; Leal M; Lopez-Galindez C; Rallon N; Alcami J; Lopez-Aldeguer J; Viciana P; Rodriguez C; Grau E; Iribarren J; Gatell JM; Garcia F;
    AIDS; 2016 May; 30(8):1209-20. PubMed ID: 26854807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rates of long-term progression in HIV-1-positive elite controllers.
    Borrell M; Fernández I; Etcheverrry F; Ugarte A; Plana M; Leal L; García F
    J Int AIDS Soc; 2021 Feb; 24(2):e25675. PubMed ID: 33619912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.
    Okulicz JF; Marconi VC; Landrum ML; Wegner S; Weintrob A; Ganesan A; Hale B; Crum-Cianflone N; Delmar J; Barthel V; Quinnan G; Agan BK; Dolan MJ;
    J Infect Dis; 2009 Dec; 200(11):1714-23. PubMed ID: 19852669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Progression in HIV-1-Infected Viremic Controllers.
    Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.
    Grabar S; Selinger-Leneman H; Abgrall S; Pialoux G; Weiss L; Costagliola D
    AIDS; 2009 Jun; 23(9):1163-9. PubMed ID: 19444075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
    Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.
    Kayongo A; Gonzalo-Gil E; Gümüşgöz E; Niwaha AJ; Semitala F; Kalyesubula R; Bagaya BS; Joloba ML; Sutton RE
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):394-398. PubMed ID: 30063647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.
    Julg B; Pereyra F; Buzón MJ; Piechocka-Trocha A; Clark MJ; Baker BM; Lian J; Miura T; Martinez-Picado J; Addo MM; Walker BD
    Clin Infect Dis; 2010 Jul; 51(2):233-8. PubMed ID: 20550452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients.
    León A; Leal L; Torres B; Lucero C; Inciarte A; Arnedo M; Plana M; Vila J; Gatell JM; García F
    AIDS; 2015 Mar; 29(6):675-81. PubMed ID: 25849831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs.
    Buckheit RW; Allen TG; Alme A; Salgado M; O'Connell KA; Huculak S; Falade-Nwulia O; Williams TM; Gallant JE; Siliciano RF; Blankson JN
    Nat Commun; 2012 Mar; 3():716. PubMed ID: 22395607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of the HIV-specific CD8+ T-cell response in an HIV elite controller after chikungunya virus infection.
    Ghiglione Y; Ruiz MJ; Salido J; Trifone C; Sued O; Martin Y; Patterson P; Laufer N; Turk G
    AIDS; 2016 Jul; 30(12):1905-11. PubMed ID: 27124898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
    Gonzalo-Gil E; Ikediobi U; Sutton RE
    Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.
    Noel N; Lerolle N; Lécuroux C; Goujard C; Venet A; Saez-Cirion A; Avettand-Fenoël V; Meyer L; Boufassa F; Lambotte O;
    PLoS One; 2015; 10(7):e0131922. PubMed ID: 26146823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.
    Boufassa F; Lechenadec J; Meyer L; Costagliola D; Hunt PW; Pereyra F; Deeks S; Pancino G; Taulera O; Lichterfeld M; Delobel P; Saez-Cirion A; Lambotte O; ; ; ;
    PLoS One; 2014; 9(1):e85516. PubMed ID: 24465584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
    Kammers K; Chen A; Monaco DR; Hudelson SE; Grant-McAuley W; Moore RD; Alter G; Deeks SG; Morrison CS; Eller LA; Blankson JN; Laeyendecker O; Ruczinski I; Eshleman SH; Larman HB
    Front Immunol; 2021; 12():740395. PubMed ID: 34512672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
    Witwer KW; Watson AK; Blankson JN; Clements JE
    Retrovirology; 2012 Jan; 9():5. PubMed ID: 22240256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
    Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
    J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elite and viremic HIV-1 controllers in West Africa.
    N'takpé JB; Gabillard D; Moh R; Gardiennet E; Toni TD; Kouame GM; Badje A; Emieme A; Karcher S; Le Carrou J; Ménan H; Danel C; Eholie SP; Rouzioux C; Anglaret X; Lambotte O
    AIDS; 2022 Jan; 36(1):29-38. PubMed ID: 34524145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
    Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
    Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
    de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.